CClinicalTrials.gg
TerminatedNCT03434080Updated Aug 22, 2025

Near-infrared Spectroscopy and Electroencephalography to Assess Cortical Activation During Motor Tasks in Infants and Toddlers With and Without Cerebral Palsy

An observational study in Autism and Cerebral Palsy, sponsored by National Institutes of Health Clinical Center (CC). Terminated at 1 site in United States. Open to participants aged 3 Months to 5 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-08-22.

Sponsored by National Institutes of Health Clinical Center (CC) · Observational

Why this study was terminated
PI Retirement
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
26
Ages
3 Months to 5 Years
Sex
All
01

Study summary

Background:

New ways to study the brain as people move include near-infrared spectroscopy (NIRS) and electroencephalography (EEG). NIRS uses laser light shone through the scalp to look at blood flow in the brain which increases with movement. EEG records electrical activity in the brain. Little is known about brain activity while children learn new motor skills. Researchers want to learn more about how small children with and without cerebral palsy use their brain to control their body. This may help them find new ways to help children move better.

Objectives:

To learn more about how infants and young children with and without cerebral palsy use their brain to move their arms and legs.

Eligibility:

Children ages 3 months - 5 years with and without cerebral palsy

Design:

Participants will be screened with:

  • Physical exam
  • Questions for the parents about the child s health

Participants will have at least 1 study session. Some may have up to 34 (all optional).

In the sessions, participants will do motor tasks along with some or all of the following:

  • Light sensors placed on the scalp, held there with a cap or Velcro straps.
  • Small metal disks placed on the scalp with a cap or straps, with gel between them.
  • Motion capture recording. Balls attached to the arms and legs by stickers, straps, or a garment are tracked by infrared and video cameras.

Motor tasks include reaching, clapping, kicking, and standing.

Participants may be placed in a toy or device that uses a motor to move their limbs.

Participants head size, hair, and skin will be assessed.

Parents will answer questions about their child s typical movements.

...

Read the detailed description

OBJECTIVE

Portable neural imaging during functional tasks is now possible utilizing noninvasive near-infrared spectroscopy (NIRS) which identifies areas of brain activity by measuring blood flow dynamics and electroencephalography (EEG) which measures electrical activity on the cortical surface. Use of these technologies for studying movement is rapidly increasing; however, investigations in children and those with neurological disorders such as cerebral palsy (CP) or autism spectrum disorder (ASD) are still in the early stages with few reports in the literature. The objectives of this protocol are to systematically compare cortical activation patterns during specified sensorimotor tasks in infants and young children with typical development (TD) to those with and at high-risk for CP and ASD, examine developmental changes in brain activation patterns that underlie the emergence of early functional or dysfunctional motor control and explore the neural and biomechanical effects of different devices that make movement easier for infants and toddlers with CP and ASD. The results are expected to increase knowledge of brain activation patterns across tasks in groups with and without neurological disorders and to suggest potential mechanisms or strategies for future clinical intervention trials.

STUDY POPULATION

The group with CP (including all infants less than 18 months who are identified as being at high-risk for CP) will consist of up to 100 children ages 3 months up to 5 years of age. The group with ASD (including all infants less than 3 years of age who are identified as being at high-risk for ASD) will consist of up to 100 children ages 3 months up to 5 years of age. The control group will consist of up to 100 children with TD within the same age range.

DESIGN

This is an observational study that will include cross-sectional and longitudinal data collection. NIRS and/or EEG responses, and kinematic and/or kinetic, force plate, wearable sensors, and/or electromyography (EMG) recordings will be collected on all participants during the performance of self-initiated motor tasks. Additionally, we will evaluate brain and motor responses to devices that aim to make movement easier for infants and children who may have difficulty initiating or performing these movements without assistance.

OUTCOME MEASURES

Primary outcomes are the magnitude, extent and location of brain activity recorded by NIRS and/or EEG within tasks across subject groups. We will also quantify changes in brain activation across ages (cross-sectional) and time (longitudinal). Secondary outcomes may include motion, force plate, wearable sensors, and EMG data to help interpret task and group differences and measures of motor abilities. The same outcome measures will be compared across ages to examine the development of cortical activation patterns and motor abilities and how these change over time and across groups with and without neurological disorders.

02

Conditions studied

  • Autism
  • Cerebral Palsy

Keywords

  • Infant and Toddler at Risk
  • Pediatric
  • Neuroimaging
  • Brain Function
  • Voluntary Movement
  • Natural History
03

Who can participate

Ages eligible
3 Months to 5 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

1. patient diagnosed with Autism or infant at high risk ASD. 2. patient diagnosed with CP or infant under 18 months for being at high risk with CP. 3. Typical Development kids (TD).

Inclusion criteria

  • All subjects must be between age 3 months up to 5 years of age.
  • A healthy volunteer, or
  • A child with or at high risk for CP or ASD:

    • An infant/child with an established diagnosis of CP, or
    • An infant less than 18 months who has been identified by a physician as being at high risk for having CP, or
    • An infant/child with an established diagnosis of ASD or
    • A child less than 3 years of age who has been deemed at high-risk for ASD or developmental delays by a physician, early intervention specialist (enrolled in early intervention services), or other qualified health professional, or
    • A younger sibling to a child diagnosed with ASD

Exclusion criteria

EXCLUSION CRITERIA:

  • Has any injury or health condition other than CP or ASD or being at-risk for having CP or ASD that affects the ability to move a body part repetitively for short periods. Examples include spinal cord injury, muscle diseases, congestive heart failure, or recently broken bones. The physician or other qualified health professioinal will discuss the child s health history during the screening to determine if participation is safe.
  • Child of investigators and children of subordinates to an investigator
  • Has a known genetic disorder that is a direct cause of the developmental delays

Additional exclusion criteria for infants and young children with or at high risk for CP:

  • Concurrent use of medicines for muscle tone (e.g., baclofen, trihexyphenedyl, dantrolene sodium, tizanidine, or carbidopa/levodopa).
  • Has had surgery involving the musculoskeletal system (bone, joints, tendons, muscles, or neurological system (brain, spinal cord, peripheral nerves) within the past year
  • Botulinum toxin injections within the past four months.
  • A history of having had a major seizure or now diagnosed as having a seizure disorder and is on medication for seizures (e.g. may have had a mild seizure(s) in the past but is not currently being treated for seizures).
  • Chronic respiratory problems that require the use of oxygen.

Additional exclusion criteria for infants and young children with or at high-risk for ASD:

  • Has had surgery involving the musculoskeletal system (bone, joints, tendons, muscles, or neurological system (brain, spinal cord, peripheral nerves) within the past year.
  • Has uncontrollable seizures (e.g. unable to be managed with medicines or treatment).

Additional exclusion criteria for infants and young children with TD

-Born preterm (defined as less than 36 weeks gestation); or birth weight significantly below normal for gestational age (SGA- small for

gestational age).

04

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
26 participants (actual)

Groups and cohorts

  • Autism Spectrum Disorder

    The group with ASD (including all infants less than 3 years of age who are identified as being at high-risk for ASD)

  • Cerebral Palsy

    The group with CP (including all infants less than 18 months who are identified as being athigh-risk for CP)

  • Typical Development toddlers infants

    The control group will consist of 50 healthy volunteers with TD

05

What researchers measure

Primary outcomes

  1. Magnitude, extent and location of brain activity recorded by NIRS and/or EEG within tasks across subject groups. We will also quantify changes in brain activation across ages (cross-sectional) and time (longitudinal).

    Data from each of the techniques will be compared across subjects group.

    Time frame: each visit

Secondary outcomes

  1. Secondary outcomes include motion and EMG data to help interpret task and group differences and measures of motor abilities. The same outcome measures will be compared across ages to examine the development of cortical activation patterns and mo...

    Outcome measures quantified the type and extent of movement.

    Time frame: Each Visit

06

Study locations

1 site
  • National Institutes of Health Clinical Center
    Bethesda, Maryland 20892, United States
07

References and documents

Individual participant data

Plan to share: Undecided — Protocol is silent in IPD sharing.

08

Registry details

Key details

Study ID
NCT03434080
Lead sponsor
National Institutes of Health Clinical Center (CC)
Responsible party
Sponsor
First posted
Feb 15, 2018
Start date
May 16, 2018
Primary completion
Aug 21, 2025
Completion
Aug 21, 2025
Last update
Aug 22, 2025

Study contacts

Diane L Damiano, Ph.D.
principal investigator · National Institutes of Health Clinical Center (CC)

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion